Company intelligence / Profile preview

Exelgyn

Paris, France

Ownership: Private
Development stage: Other

Overview

Exelgyn is a French pharmaceutical company specializing in women's health, with a primary focus on medical termination of pregnancy and reproductive medicine. Founded in 1997 by Edouard Sakiz, the former CEO of Roussel-Uclaf, the company was established to ensure the global availability of mifepristone. Its flagship product, Mifegyne, is a gold standard in medical abortion and is distributed in numerous countries worldwide. Exelgyn also provides misoprostol formulations, such as MisoOne, to be used in combination with mifepristone. Since 2010, the company has operated as a subsidiary of Nordic Pharma, continuing its mission to provide safe pharmacological solutions for gynecological and obstetric care.

Therapeutic areas: Women's Health
Modalities: Small moleculeHormone
Industry: Biotech

Partnerships

Nordic Pharma

Beyond the preview

Go deeper on Exelgyn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exelgyn.

Explore the full profile